Business Wire

Fluence Fixtures Lead to Improved Product for Cannabis Cultivators Worldwide

Share

Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is helping global cannabis cultivators find operational stability by helping growers address cost efficiencies amid ongoing industry headwinds and energy market volatility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230330005252/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Fluence LEDs provide high-efficiency and high-quality lighting without a significant impact on the localized power grid, or on temperature and humidity in the grow space at Chroni-Co. (Photo: Business Wire)

Cannabis growers around the world are feeling the effects of higher operating costs due to supply chain challenges and rapidly fluctuating energy prices, making it more important than ever for cultivators to invest in and integrate reliable, cost-saving solutions. Fluence’s LED technology VYPR series offer growers increased control over energy expenditure and a greater ability to customize light spectrum based on what works best for specific crops.

Replacing legacy high-pressure sodium (HPS) lighting systems with Fluence’s energy-efficient and environmentally friendly LED fixtures is one of the easiest ways to achieve cost savings and improve energy efficiency as well as reduce the impact on local power grids. Cannabis cultivators around the world, including many in North America, have also cut capital expenses by leveraging Fluence’s deep experience and guidance in helping partners receive energy efficiency rebates or subsidies in states with qualifying programs.

“Fluence’s LED lighting solutions are helping cannabis cultivators in North America and across Europe, the Middle East and Africa advance operational efficiency and profitability,” said Steve Graves, senior vice president of strategy and product at Fluence. “The VYPR product line enables growers to transition away from HPS lighting systems and save tens of thousands of dollars per year in energy consumption.”

Fluence’s horticultural and technical experts help partners to design, tailor and apply lighting solutions to specific facility footprints and meet their goals for plant growth and consistency. While growers have traditionally had to plan environmental control around the high heat output of HPS fixtures, VYPR fixtures and all other Fluence LEDs reduce interference with temperature and humidity in the grow space. Fluence’s in-house research and horticultural teams work closely with partners pre-, during and post-installation to adapt to the flexibility and control LEDs offer over environmental conditions for plant growth and operational scale.

Chroni-Co, a tenth-generation family-run commercial agriculture company in South Africa, chose to introduce medical cannabis into its portfolio of crops in 2019. They turned to Fluence for its industry leadership in LED grow lights and professional support for companies entering or already in cannabis production. Chroni-Co has taken advantage of the full range of Fluence products for upscaling production, sustainability and eco-friendliness, incorporating VYPR 2P, VYPR 3P and SPYDR 2X to aid the transition to cannabis cultivation while navigating growing a warm-weather crop against South Africa’s chilly winters.

“When we entered the medical cannabis space, we wanted to identify a lighting partner with a proven track record of supporting successful cannabis grows on a global scale whose work is backed by science and research,” said James Simpson, director and founder of Chroni-Co. “After meeting with Fluence, we knew we’d found a perfect match. Fluence’s VYPR and SPYDR solutions have helped us reduce our emissions and while lowering our operating expenses. More importantly, they’ve helped us provide our customers with a better, more consistent product.”

Early results at Chroni-Co are incredibly promising, with Fluence LEDs leading to a 30% increase in cannabinoid levels and improved morphology in cannabis plants—demonstrating the ability of Fluence products like VYPR and SPYDR to build highly successful, environmentally friendly cannabis harvests in harsh winter environments by offering better heat management and providing a balance for the lack of natural sunlight compared to HPS fixtures.

“Helping science-forward partners achieve a more consistent product and a healthier bottom line is the driving force behind what we do at Fluence,” said Timo Bongartz, general manager for Europe, the Middle East and Africa at Fluence. “Beneath Fluence LED technology, Chroni-Co’s medical-grade cannabis started as and has remained top-quality flower that is now sold to patients across Germany, a testament to the caliber of product and the ongoing globalization of the cannabis market that we are proud to play a part in.”

Fluence LED lighting solutions are available for purchase by licensed cultivators in territories in which the cultivation of cannabis is legal. For more information on Fluence, visit www.fluence.science.

About Fluence

Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (89) 6213-3939

For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye